SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer, Director | 2026-07-14 | Open-market buy | 34364 | $50K |
| PACE GARY W | Director | 2026-07-14 | Open-market buy | 687285 | $1000K |
| Mohindru Mani | Chief Executive Officer, Director | 2026-06-18 | Open-market buy | 24703 | $30K |
| PACE GARY W | Director | 2026-06-18 | Open-market buy | 30000 | $37K |
| PACE GARY W | Director | 2025-07-30 | Open-market buy | 275000 | $674K |
| PACE GARY W | Director | 2025-07-30 | Open-market buy | 15000 | $37K |
Cardiff Oncology completed a registered direct offering of approximately 8.6 million shares of common stock and accompanying warrants at $1.05 per share, with officers and directors purchasing an additional ~731,707 insider shares at $1.435 per share, generating approximately $10.05 million in gross proceeds for working capital and general corporate purposes.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.
View raw filing on EDGAR →Cardiff Oncology disclosed Phase 2 CRDF-004 clinical trial data and registrational study plans for onvansertib via an investor presentation under Regulation FD. While this represents material clinical development information that would affect investor assessment of the company's pipeline and regulatory pathway, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, executive change, or other specifically defined event). The disclosure is material because clinical trial results and regulatory strategy are central to a biotech company's valuation and investor decision-making.
View raw filing on EDGAR →The filing discloses a material dispute between Cardiff Oncology and Nerviano Medical Sciences involving a license agreement termination and competing claims of material breach. Cardiff filed a lawsuit on May 19, 2026 seeking injunctive relief and declaratory judgment, and NMS responded with a termination notice on May 27, 2026 alleging breaches related to patent inventorship and failure to conduct development activities for onvansertib. While Item 1.01 nominally covers "Entry into a Material Definitive Agreement," the substance here is a material litigation and contractual dispute that would significantly affect a reasonable investor's assessment of the company's rights to key intellectual property and product development obligations.
View raw filing on EDGAR →Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences in U.S. District Court for the Southern District of California seeking injunctive relief and declaratory judgment regarding an alleged material breach of a license agreement for onvansertib. The dispute centers on patent inventorship obligations and continuation patent applications, with Cardiff disputing NMS's breach allegations. This is a material litigation event that would affect investor assessment of the company's ability to maintain its license rights and product development.
View raw filing on EDGAR →